ArticleThe Journal of antibiotics2015
Activity of lipophilic and hydrophilic drugs against dormant and replicating Mycobacterium tuberculosis.
Article in The Journal of antibiotics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Nanodiamonds Co-Localize withPharmaceutics · 2026Article
- A comprehensive review of cluster methods for drug-drug interaction network.Quantitative biology (Beijing, China) · 2026Review
- Structure-Guided Development of Mycobacterial Thymidine Monophosphate Kinase (MtbTMPK) Inhibitors: Unlocking New Frontiers in Tuberculosis Research.Current topics in medicinal chemistry · 2026Review
- Drug Design and Delivery for Intracellular Bacteria: Emerging Paradigms.Drug development research · 2025Review
- TamGen: drug design with target-aware molecule generation through a chemical language model.Nature communications · 2024Article
- Free Energy Barriers for Passive Drug Transport through theInternational journal of molecular sciences · 2024Article
- Effect of Host Cholesterol on the Membrane Dynamics of Outer Membrane Lipids of Mycobacteria.Chemistry, an Asian journal · 2023Article
- Article
- Formulation and Scale-up of Delamanid Nanoparticles via Emulsification for Oral Tuberculosis Treatment.Molecular pharmaceutics · 2023Article
- Eradication of Drug-TolerantMicroorganisms · 2023Review
- Synthesis and Structure-Activity Relationships for the Anti-Mycobacterial Activity of 3-Phenyl-Pharmaceuticals (Basel, Switzerland) · 2022Article
- Adaptation and Resistance: HowMicroorganisms · 2022Article
- Activity of Drug Combinations againstMicroorganisms · 2022Article
- Alkaloids ofBiomolecules · 2022Article
- The Biological and Clinical Aspects of a Latent Tuberculosis Infection.Tropical medicine and infectious disease · 2022Review
- Structure-aided optimization of non-nucleoside M. tuberculosis thymidylate kinase inhibitors.European journal of medicinal chemistry · 2021Article
- Semisynthetic Derivatives of Selected Amaryllidaceae Alkaloids as a New Class of Antimycobacterial Agents.Molecules (Basel, Switzerland) · 2021Article
- Lipid polymer hybrid nanocarriers as a combinatory platform for different anti-SARS-CoV-2 drugs supported by computational studies.RSC advances · 2021Article
- Facile synthesis and antimycobacterial activity of isoniazid, pyrazinamide and ciprofloxacin derivatives.Chemical biology & drug design · 2021Article
- Easy-To-Access Quinolone Derivatives Exhibiting Antibacterial and Anti-Parasitic Activities.Molecules (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
25944535What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.